Photo from wikipedia
Anti-CD30 therapy for Hodgkin lymphoma led to transient loss of detectable CD4+ T-cell HIV RNA and a decrease in residual plasma viremia. Targeting nonviral markers expressed on HIV-1 transcriptionally active… Click to show full abstract
Anti-CD30 therapy for Hodgkin lymphoma led to transient loss of detectable CD4+ T-cell HIV RNA and a decrease in residual plasma viremia. Targeting nonviral markers expressed on HIV-1 transcriptionally active cells may lead to reduced measures of HIV-1 persistence.
Keywords:
hodgkin lymphoma;
therapy hodgkin;
loss detectable;
transient loss;
anti cd30;
cd30 therapy
Journal Title: Blood advances
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood advances
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!